Dosing of carboplatin in a patient with amputated legs: A case report. (December 2014)

• Record Type: Journal Article
• Authors: van Gorp, F; van Rens, MThM; Kuck, EM; Rozemeijer, R; Huitema, ADR; Brouwers, EEM
• Is Part Of: Journal of oncology pharmacy practice. Volume 20:Number 6(2014)
• Page Start: 473
• Page End: 475
• Publication Date: 2014-12
• Subjects: Carboplatin -- small-cell lung carcinoma -- amputation -- renal function -- therapeutic drug monitoring; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155213514470
• Languages: English
• ISSNs: 1078-1552

Abstract

Carboplatin is a platinum derivative that is commonly used in combination chemotherapy for treatment of several malignancies, including small-cell lung carcinoma (SCLC). Because the estimated glomerular filtration rate, and therefore the carboplatin dose, is based on the serum creatinine level, dosing of carboplatin for amputees is a challenge. This case report describes how serum carboplatin levels were used to determine the most suitable carboplatin dose for an amputee. The patient received four cycles of etoposide in combination with carboplatin area under the curve =5 mg·min/ml, with a dose reduction of 25% and concurrent radiotherapy. The measured area under the curve was found to be 3.41 mg·min/ml, while the target area under the curve was 3.75 mg·min/ml (75% of 5 mg·min/ml). Therefore, for the next cycles, the carboplatin dose was calculated using the Calvert formula. No recurrence of disease was seen within two years after completion of therapy. This case demonstrates that therapeutic drug monitoring can successfully be used to determine the carboplatin dose for an amputee.